ArticleBioconjugate chemistry2010
Glycan encapsulated gold nanoparticles selectively inhibit shiga toxins 1 and 2.
Article in Bioconjugate chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 59 citations in OpenAlex.
- Gold Nanoparticles: Multifunctional Properties, Synthesis, and Future Prospects.Nanomaterials (Basel, Switzerland) · 2024Review
- Phenotypic and genomic comparison of three human outbreak and one cattle-associated Shiga toxin-producingMicrobiology spectrum · 2024Article
- Glycomimetics for the inhibition and modulation of lectins.Chemical Society reviews · 2023Review
- EnterohemorrhagicInternational journal of molecular sciences · 2022Review
- Glyco-nanotechnology: A biomedical perspective.Nanomedicine : nanotechnology, biology, and medicine · 2022Review
- Selective treatment of intracellular bacterial infections using host cell-targeted bioorthogonal nanozymes.Materials horizons · 2022Article
- Recent Advances in the Application of Glycan-Modified Self-Assembled Monolayers.Advances in chemistry research · 2020Article
- A nanobody targeting the translocated intimin receptor inhibits the attachment of enterohemorrhagic E. coli to human colonic mucosa.PLoS pathogens · 2019Article
- Functional Glyco-Nanogels for Multivalent Interaction with Lectins.Molecules (Basel, Switzerland) · 2019Article
- The glyconanoparticle as carrier for drug delivery.Drug delivery · 2018Review
- T-Cell-Mimicking Nanoparticles Can Neutralize HIV Infectivity.Advanced materials (Deerfield Beach, Fla.) · 2018Article
- Degradation and inactivation of Shiga toxins by nitrogen gas plasma.AMB Express · 2017Article
- Cell membrane-derived nanomaterials for biomedical applications.Biomaterials · 2017Review
- Glyco-gold nanoparticles: synthesis and applications.Beilstein journal of organic chemistry · 2017Review
- Glyconanomaterials for biosensing applications.Biosensors & bioelectronics · 2016Review
- Inhibiting Microbial Toxins Using Plant-Derived Compounds and Plant Extracts.Medicines (Basel, Switzerland) · 2015Review
- Glyconanomaterials: Emerging applications in biomedical research.Nano research · 2014Article
- Influence of ligand presentation density on the molecular recognition of mannose-functionalised glyconanoparticles by bacterial lectin BC2L-A.Glycoconjugate journal · 2013Article
- Interaction of silver nanoparticles with serum proteins affects their antimicrobial activity in vivo.Antimicrobial agents and chemotherapy · 2013Article
- Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants.Infection and immunity · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Shiga toxins (Stx) released by Escherichia coli O157:H7 and Shigella dysentriae cause life-threatening conditions that include hemolytic uremic syndrome (HUS), kidney failure, and neurological complications. Cellular entry is mediated by the B-subunit of the AB(5) toxin, which recognizes cell surface glycolipids present in lipid raft-like structures. We developed gold glyconanoparticles that present a multivalent display similar to the cell surface glycolipids to compete for these toxins. These highly soluble glyconanoparticles were nontoxic to the Vero monkey kidney cell line and protected Vero cells from Stx-mediated toxicity in a dose-dependent manner. The inhibition is highly dependent on the structure and density of the glycans; selective inhibition of Stx1 and the more clinically relevant Stx2 was achieved. Interestingly, natural variants of Stx2, Stx2c, and Stx2d possessing minimal amino acid variation in the receptor binding site of the B-subunit or changes in the A-subunit were not neutralized by either the Stx1- or Stx2-specific gold glyconanoparticles. Our results suggest that tailored glyconanoparticles that mimic the natural display of glycans in lipid rafts could serve as potential therapeutics for Stx1 and Stx2. However, a few amino acid changes in emerging Stx2 variants can change receptor specificity, and further research is needed to develop receptor mimics for the emerging variants of Stx2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.